TransCode Therapeutics (RNAZ) Stock Forecast: StockMap's 2-Week Call
RNAZ stock forecast: StockMap's model calls TransCode Therapeutics Strong Underperform for the two weeks after the Nov 19 close: it expects RNAZ to trail the growth index. It is a call on the gap, not a price target. Right in 4 of 6 two-week windows on RNAZ since Aug 21; by chance, a call on the same dates was right 59% of the time.
TransCode Therapeutics last closed at $1.30, -2.99% on the session.
Against the IVW growth benchmark the position is -0.66% over the forecast window.
TransCode Therapeutics' market cap is $22.58M as of November 19, 2026.
Calls down ↘: the model's call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -54 (behind).
Where RNAZ sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 3 bullish and 12 bearish.
Agreement across those insights is 80%.
49 daily calls for RNAZ so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks TransCode Therapeutics in the 99th percentile on return on equity, where 100 is best.
TransCode Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks TransCode Therapeutics as the 338th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite TransCode Therapeutics ranks 365th of 394 in the group, against a group median of -0.27.